(Q30433670)

English

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

1 reference

based on heuristic

inferred from title

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study (English)

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

Carolyn Y. Muller

8

object named as

Carolyn Y Muller

0 references

Daniela E. Matei

7

object named as

Daniela Matei

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Bradley J. Monk

5

object named as

Bradley J Monk

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

author name string

Koen De Geest

1

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

John A Blessing

2

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Robert T Morris

3

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

S Diane Yamada

4

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Susan L Zweizig

6

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

William E Richards

9

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

language of work or name

0 references

publication date

16 November 2009

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

28

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

1

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

149-153

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Evidence for microtubule target engagement in tumors of patients receiving ixabepilone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Chromosomal instability, colorectal cancer and taxane resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Epothilones: mechanism of action and biologic activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Do beta-tubulin mutations have a role in resistance to chemotherapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Novel molecules that interact with microtubules and have functional activity similar to Taxol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Epothilones and new analogues of the microtubule modulators in taxane-resistant disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Optimal flexible designs in phase II clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New tubulin targeting agents currently in clinical development

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.24.1455

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30433670&oldid=2032769396"